336-16358-57437
1 vaccination
1 coded response
6 check-ins
1 free-text entry
1 call case
- Sex
- Female
- Age at first dose
- 21-25
- ZIP prefix
- 473 / IN
- Registered
- 2022-01-02
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-12-30
Dose 1 — Janssen/Johnson & Johnson
-
2022-01-02
Registered in v-safe
-
2022-01-02
Health check-in — days 1–6 daily, dose 1Feeling: Good · Site: Pain · Fatigue or tirednessAdult check-in
- 2022-01-03
- 2022-01-05
- 2022-01-08
- 2022-01-22
-
2022-02-05
Survey response — day 35, single doseMedDRA: Nasopharyngitis — Feeling: Poor · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationFree text: ColdMedDRA releases: 2024-11 · check-in free text available
-
2022-02-05
Report sent to call center — day 35, single doseBe unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prTelehealth, virtual health, or email health consultation · 1 call case(s)
- 2022-02-09
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-12-30 | Janssen/Johnson & Johnson | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2022-02-05 | Unsuccessful |
Free text
Release 11 — day 35, single dose
Symptoms: Cold
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Nasopharyngitis | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release